SMC accepts 14 new medicines for use by NHS Scotland
The decisions bring a raft of new treatment options for conditions including epilepsy, depression and cancer
Read More
Tag: Perjeta
US nod for Roche’s breast cancer combo
The therapy marks Roche’s first combination of two monoclonal antibodies administered in a single subcutaneous injection
Read More
NICE changes its mind on Perjeta
NICE has changed its mind and recommended Roche’s Perjeta for a new breast cancer indication.
Read More
SMC OK’s four meds for NHS use, including Roche’s Perjeta
The Scottish Medicines Consortium (SMC) has recommended four medicines – including Roche’s breast cancer drug Perjeta – for use on the NHS.
Read More
SMC accepts four medicines for NHS use
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Read More
NICE sticks with ‘no’ for use of Perjeta after breast cancer surgery
NICE is sticking with its position that Roche’s Perjeta is not cost-effective enough to be used by the NHS post surgery to prevent breast cancer recurrence.
Read More
NICE rejects adjuvant use of Perjeta post-surgery
The National Institute for Health and Care Excellence says adjuvant use of Roche’s breast cancer drug Perjeta in patients who have had surgery is not cost effective for the NHS.
Read More
NICE backs Roche’s Perjeta for breast cancer
The National Institute for Health and Care Excellence has issued a final green light securing routine NHS funding for Roche’s Perjeta in patients with a certain type of breast cancer.
Read More
Green light for Perjeta/Herceptin combo
Roche group Genentech has secured approval of Perjeta in combination with Herceptin (trastuzumab) and chemotherapy for adjuvant treatment of a specific type of early breast cancer in the US.
Read More
NHS England, Roche come to agreement on Perjeta
NHS England and Roche have agreed a confidential commercial agreement on the price of Perjeta for certain patients with breast cancer.
Read More
NICE backs Roche’s Perjeta, but bars Kadcyla
Patients with certain forms of breast cancer should be able to get routine NHS access to Roche’s Perjeta in England and Wales in the next three months following a recent final nod from NICE, but Kadcyla has been rejected by the cost regulator.
Read More
Roche drops price of breast cancer drug for NICE approval
The National Institute for Health and Care Excellence has changed its position on the routine use of Roche’s Perjeta to treat a certain form of breast cancer on the NHS in England and Wales.
Read More
- Storm Therapeutics and AlidaBio launch collaboration to advance RNA‑targeting cancer therapies
- Excellence adventure
- MHRA approves Nucala for eosinophilic COPD in adults on triple therapy
- Bial launches new sublingual Parkinson’s treatment in UK
- Acesion Pharma launches phase 2 trial of AP31969 in atrial fibrillation
